Once counterculture staples, LSD and magic mushrooms are starting to trip out another world: psychiatry. A smallbut rapidly growinggroup of doctors is embracing the drugs as powerful tools against a myriad of mental demons. People suffering from depression, substance abuse, and post-traumatic stress disorder (PTSD) have all benefited from psychedelics in small controlled trials. Psychedelics, over 50 years after the Summer of Love, have once again taken flight.
With one caveat: they get people high. While a perk for recreational users, the mind-altering effects can be a serious detriment to patients. For now, treatments are carefully administered and monitored inside clinics rather than patients taking pills at home. Regulatory hurdles further prohibit widespread adoption.
But what if theres a way to strip away the high and leave only the drugs therapeutic effects?
Enter crystals. This week, a team extracted and crystallized the structure of psychoactive drugs docking in the brain. Using X-rays, they mapped out the interactions at the nanoscale level, teasing apart those that can lead to hallucinations from those that can calm troubled minds. Knowledge in hand, they engineered several synthetic cousins of LSD, which helped quell depressive symptoms in mice without signs of the critters getting high.
While it could be a long road from mice to men, the study is one in a series of high-profile works that seek to strip the hallucinogenic magic from psychedelics, instead adding a sprinkle of healing magic. For now, they wont be silver bulletsthe mice needed a hefty dose to dampen their depression, which is a red flag for potential side effects.
But the implications are profound. If validated in humans, the drugs would lay the groundwork for an entirely new treatment regime for mental troubles that haunt millions of people.
This work is going to generate a lot of interest, Dr. Bryan Roth at the University of North Carolina School of Medicine, an expert in the field who was not involved in the study, said to Science.
Psychedelics were all the rave in the 50s and 60s, and not just in the party scene, but also in psychiatry. At the time, treating patients with LSD, psilocybin (the active component in magic mushrooms), or MDMA (also known as molly or ecstasy) was considered a promising alternative to other therapies for restoring health and autonomy for people confined long-term in asylums. Over the decade, scientists tested roughly 40,000 people in over 1,000 studies for treatment of mental health and addiction issues.
Despite initially promising (though rudimentary) results, the studies lurched to a halt when psychedelics were banned as a backlash to widespread recreational use.
Yet neuroscientists never stopped examining their potential, even at the risk of their careers. A breakthrough came in the 2010s, when several studies showed that ketamine, a horse tranquilizer and party drug, had jaw-dropping effects for depression. Unlike other antidepressants, which often take months to workif they work at allketamine triggered beneficial effects in some people with just one dose, and within hours.
Initially met with skepticism and considered too good to be true, rigorous studies further showed that in mice, ketamine boosted the birth of new neurons in the brain while tweaking neural networks to be more adaptable. In 2019, a form of ketamine was approved by the FDA as the first truly new antidepressant in decades, hailed as a game changer for depression and a turning point for the return of psychedelics as a potential therapeutic force. It also immediately raised the question: can we make a non-hallucinogenic alternative?
As ketamine began its rebound into psychiatric prominence, other drugsincluding LSD, psilocybin, and MDMAalso started their arduous journeys of reentering medical respectability. Between 2010 and 2020 clinical trials tripled, with several showing dramatic effects. One trial found that seven out of ten people who took psilocybin reduced their symptoms by half. Other clinical trials, mostly conducted in the UK and Canada, are entering late stage.
To overcome regulatory hurdles, however, structural biologists have taken a different route: altering the structure of these chemicals, in turn stripping away their ability to trigger an unwanted trip.
It starts with visualizing where the chemicals impact the brain. The crux is a receptor called 5-HT2AR. The receptor isnt evolved to get us high; rather, its a critical protein dock for serotonina brain chemical or neurotransmitterthats involved in many of our base functions. Mood is one of them, which is why most common antidepressants today target these receptors.
Like the Los Angeles port, 5-HT2AR has multiple docking sites for chemicals, each triggering a different supply chain route. Depending on the docking station, the same cargothe drugchanges how the neuron reacts by recruiting other molecular providers. Depending on those providers, the drug tweaks the neural circuit in diverse ways, altering the brains response to the drug.
In the new study the team hunted down the provider proteins that trigger antidepressant effects. They first doused multiple mouse brains with different drugs, including LSD, magic mushrooms, serotonin, and a non-hallucinogenic therapy for Parkinsons disease. They then crystallized the 5-HT2AR dock and examined how the chemicals interacted with it at the atomic scale with X-ray beams.
Surprisingly, many psychedelics turned out to be shape-shifters. Rather than docking at one spot, they were able to contort and bind to another nearby cavity. Turning to mice, they teased apart how the different docks worked. One dock, for example, led the mice to twitch their heads, a sign of getting high. Another, when tested for depression, alleviated the symptoms.
Guided by the 5-HT2ARs docking map, the team engineered multiple LSD cousins that preferably bind to the anti-depressant dock. Repeating the experiment, they found two chemicals (with the non-catchy names of IHCH-7079 and IHCH-7806) that had antidepressant activity, without the head-twitching normally seen with LSD or psilocybin.
The study is one of many following the recipe towards a new generation of mind-healing rather than mind-bending substances. How they work remain a mystery, which is why intricate scrutiny of 5-HT2AR and other serotonin receptors is the current playbook.
On the front line are Dr. David Olson at the University of California, Davis, and Dr. Bryan Roth at UNC-Chapel Hill. Several years back, Olson synthesized near a dozen chemicals similar to LSD, with a promising result called TBG (tabernanthalog) that also binds to serotonin receptors. In mice, the drug boosted the neuronal infrastructure for learning, and cut down substance-seeking behavior in rodents. Mid-2021, a single dose of the drug was further found to be effective for stress disorders in mice. Delix Therapeutics, a company co-founded by Olson, is rapidly exploring the new drugs for clinical use, with trials potentially starting later this year.
Meanwhile, Roth has worked to decipher the structure of 5-HT2AR when bound to psychedelic compounds. The seminal study, in 2020, gained a first glimpse into how they act. Given the remarkable efficacy of psilocybin for depression (in Phase II trials), we are confident our findings will accelerate the discovery of fast-acting antidepressants and potentially new drugs to treat other conditions, such as severe anxiety and substance use disorder, he said at the time.
For now, the authors preach caution. Similar to previous non-hallucinogenic cousins, their molecules need a high dose to see anti-depressant effects. But the new structural maps add to a growing atlas to help guide non-hallucinogenic drugs forward. This additional structural data will aid efforts to design new antidepressants as well as antipsychotics, said Olson.
Image Credit: GDJ / 10433 images
Looking for ways to stay ahead of the pace of change? Rethink whats possible. Join a highly curated, exclusive cohort of 80 executives for Singularitys flagship Executive Program (EP), a five-day, fully immersive leadership transformation program that disrupts existing ways of thinking. Discover a new mindset, toolset and network of fellow futurists committed to finding solutions to the fast pace of change in the world. Click here to learn more and apply today!
View post:
Psychedelics Without the Trip Could Be 'Healing Magic' for Mental Health - Singularity Hub
- How an NHL Enforcer Broke His Body and Turned to Psychedelics to Heal His Brain - Rolling Stone - June 22nd, 2022
- The top psychedelic drug developers leading the market - Labiotech.eu - June 22nd, 2022
- Numinus Applies for International Patent Filing of Psychedelics Production Process - Yahoo Finance - June 22nd, 2022
- Two psychedelic-related initiatives may be on the 2022 Colorado ballot - Denver 7 Colorado News - June 22nd, 2022
- Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights - Business Wire - June 22nd, 2022
- SPOTLIGHT IN FOCUS - The Rise of Psychedelic Therapy - Psychedelic Spotlight - June 22nd, 2022
- Rapper Vic Mensa has a more badass fitness routine than you thanks to martial arts, psychedelics and meditation - British GQ - June 22nd, 2022
- What is Ego Death And How Does it Work? - Benzinga - Benzinga - June 22nd, 2022
- Anecdotal Evidence and the Need for Trials of Psychedelics in Headache Disorders: Bryan Roth, MD, PhD - Neurology Live - June 11th, 2022
- Stephen Asma: My father's experience with morphine in hospice showed me the healing joy of altered states - Chicago Tribune - June 11th, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of May 30 - The Dales Report - June 5th, 2022
- Psychedelic Wellness: 5 Magical Benefits of Magic Mushrooms - Longevity LIVE - Longevity LIVE - June 5th, 2022
- 'Magic mushrooms drug could help depression sufferers in the years to come' - Irish Mirror - June 5th, 2022
- Tripping over the potential of psychedelics for autism | Spectrum - Spectrum - June 3rd, 2022
- Can you take the trip out of psychedelics and still treat depression? - New Scientist - June 3rd, 2022
- We spark curiosity: how the psychedelics industry is taking on Davos - The Guardian - June 3rd, 2022
- Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy - Business Wire - June 3rd, 2022
- Ketamine can treat depression but teletherapy could make it accessible - Inverse - June 3rd, 2022
- 2022-06-01 | PINL:EHVVF | Press Release | ehave Inc - Stockhouse - June 3rd, 2022
- VIDEO: The Weekly Weed Report (05-31-22) - Investing Daily - Investing Daily - June 3rd, 2022
- Psychedelics Companies in Oregon Will Have to Grapple With 280E - Business Insider - May 21st, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of May 16 - The Dales Report - May 21st, 2022
- Psychedelics and Mindfulness: The Future of Mental Health? | Microdose - Microdose Psychedelic Insights - May 21st, 2022
- CATALYST Summit: 3 Psychedelic Speakers to Catch This Weekend - Psychedelic Spotlight - May 21st, 2022
- 'I took ketamine to treat my severe depression' - iNews - May 21st, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of May 9 - The Dales Report - May 15th, 2022
- Psychedelic Patents are Broken Because the Patent System Is Broken - VICE - May 15th, 2022
- Magic mushrooms are on WeHos mind - WEHOville - May 15th, 2022
- Behind the Scenes on the First Study To Compare the Effects of LSD and Psilocybin - Technology Networks - May 15th, 2022
- Revitalist's Strategic Initiatives Continue to Exceed Expectations for Execution Giving Company Record High Revenues Since Opening in 2018. - Business... - May 15th, 2022
- MDMA as medicine: Stemming the tide of veteran suicides in Western North Carolina - Smoky Mountain News - May 15th, 2022
- Cybin's CYB0004 Shows Positive Preclinical Results Over ... - May 3rd, 2022
- Psychedelics played role in Wallace Falls hiker's death ... - May 3rd, 2022
- The Mainstream Healthcare VCs Dipping Their Toes Into Psychedelics - Business Insider - May 3rd, 2022
- LSD Is Back On Campus, But This Time It's Approved - Green Market Report - May 3rd, 2022
- Mixing mushrooms and alcohol: What you need to know - Medical News Today - May 3rd, 2022
- Mycotopia Therapies Partners with Public Policy Specialist PsychedelicsEUROPE to Explore Opportunities in the European Market - GlobeNewswire - May 3rd, 2022
- Pharmadrug Advances Opthalmology Program with Final Selection of Lead DMT-Analogue to Provide Sustained Control of Elevated Intraocular Pressure for... - May 3rd, 2022
- Bicycle Day: Honoring The Onset Of The Psychedelic Revolution As It Zooms Across The Globe - Forbes - April 15th, 2022
- Psilocybin Rewires the Brain for People with Depression - University of California, San Francisco - April 15th, 2022
- Field Trip Health Houston's psychedelic healing with ketamine helps patient with depressive anxiety - Houston Chronicle - April 15th, 2022
- Mental Health Week: Magnetic Stimulation, Psychedelics and Tai Chi How Treatments For Anxiety And Depression Are Growing - KPCC - April 15th, 2022
- Psychedelics Want To Win Over The Sleep Aid Market - Green Market Report - April 15th, 2022
- Terran Biosciences and Blumentech SL announce the acquisition of a patent portfolio covering the groundbreaking discoveries of prominent psychedelics... - April 15th, 2022
- Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds - Yahoo Finance - April 15th, 2022
- Experts discuss the intersections of cannabis, health and food - CSU Pueblo Today - April 15th, 2022
- Psychedelics - PMC - April 11th, 2022
- Psychedelics - PubMed - April 11th, 2022
- Peace with psychedelics: Palestinians, Israelis took ayahuasca - Big Think - April 11th, 2022
- Study maps psychedelic-induced changes in consciousness to specific regions of the brain - PsyPost - April 11th, 2022
- The Next Big Addiction Treatment - The New York Times - April 11th, 2022
- SABI Mind and Reverie Psychedelics Partner To Expand Research Into Psychedelic-Assisted Therapies - Benzi - Benzinga - April 11th, 2022
- Jaden Smith on His Trippy Summer '22 Collection and the Power of Mushrooms - Complex - April 11th, 2022
- Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022 - Business Wire - March 31st, 2022
- Psychedelics' Interaction With Psych Meds: More Q's Than A's - Medscape - March 31st, 2022
- The Insights Psychedelics Give You Arent Always True - March 18th, 2022
- Stage Set for Psychedelics Stock Boom: Here's Where ... - March 18th, 2022
- SXSW stage is a collision of weed, metaverse, NFTs, acid and saving the planet - PitchBook News & Analysis - March 18th, 2022
- Jaden Smith Recalls His Experience With Psychedelic Mushrooms: Everything Just Becomes So Beautiful - Koimoi - March 18th, 2022
- Michigan Activists Submit Psychedelics Decriminalization ... - March 17th, 2022
- Psychedelics and the Future of Psychiatry - March 17th, 2022
- Mind Cure Gives Up On Psychedelics, Fires C-Suite, And Reverts To Shell After Strategic Review - The Deep Dive - March 17th, 2022
- A Fully-Seated Audience Takes Post-Punk with the Psychedelic Furs - Cornell University The Cornell Daily Sun - March 17th, 2022
- 5 people who used psychedelics to treat PTSD describe their trips - Business Insider - March 15th, 2022
- What is Microdosing, and Does it Work? - The New York Times - March 15th, 2022
- Bolt's Breslow Teams With Psychedelics Founder on Crypto Pharma Startup - The Information - March 15th, 2022
- Enveric, University of Calgary to study psychedelic therapy - OutSourcing-Pharma.com - March 15th, 2022
- Psychedelic therapy integral to ancient societies may be coming to Pennsylvania - 90.5 WESA - March 15th, 2022
- The Bluntness Debuts The BLUNTNESS/100 Its Inaugural List of the 100 Most Influential People in Cannabis & Psychedelics - 69News WFMZ-TV - March 15th, 2022
- Former NFL Player Eben Britton On His New Book, And The Tools He Used To Rebuild His Life (Including Psychedelics) - The Dales Report - March 15th, 2022
- Made by Marlo: Max Ingersoll and the Meaning of Meditation - Harvard Independent - March 15th, 2022
- What are Psychedelics? - March 8th, 2022
- Get the Legal Psychedelics for Sale in the USA ... - March 8th, 2022
- Fireside Project manifests a $200K fund to improve access to careers in psychedelic health - TechCrunch - March 8th, 2022
- Oklahoma bill to study mental health effects of 'shrooms' advances - Oklahoman.com - March 8th, 2022
- Terran Biosciences and University of Maryland, Baltimore announce exclusive licensing deal for a portfolio of patents and data supporting novel... - March 8th, 2022
- Cybin Teams With Chopra Foundation To Foster Psychedelics Awareness - Benzinga - Benzinga - March 8th, 2022
- How My Drinking Was Used to Deny Me Treatment for Depression - Filter - March 8th, 2022
- Seelos Therapeutics: Year-End Results and Business Highlights Microdose - Microdose Psychedelic Insights - March 8th, 2022
- No worries: Severe anxiety disorders to get the Incannex, Monash Uni treatment via psychedelics within vir ... - Stockhead - March 8th, 2022